Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01906372 · ClinicalTrials.gov registry record · Phase 2
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
A Phase 2 study, sponsored by Rohit Aggarwal, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01906372 is a Phase 2 study that has completed, run by Rohit Aggarwal, MD. The registered enrollment target is 12 participants.
The verdict
NCT01906372, a Phase 2 study, has completed, sponsored by Rohit Aggarwal, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the effectiveness of the study drug, ACTH Gel in people diagnosed with dermatomyositis a disease that causes muscle weakness and is associated with a rash (DM) or polymyositis (PM) a disease that causes muscle weakness without a rash. The study doctors want to evaluate whether ACTH Gel will improve the symptoms of this disease. This drug is approved by the Food and Drug Administration (FDA) for dermatomyositis (DM) and polymyositis (PM). ACTH gel has been an FDA-approved treatment for myositis since 1952, and in 2010 the FDA retained PM and DM as diseases approved for ACTH gel use.
Interventions
- DRUG Adrenocorticotropic Hormone Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01906372
The ClinicalTrials.gov registry entry for NCT01906372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rohit Aggarwal, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adrenocorticotropic Hormone Gel is the first listed.
NCT01906372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01906372 about?
NCT01906372 is a clinical study titled "Acthar in Treatment of Refractory Dermatomyositis and Polymyositis". The purpose of this research study is to evaluate the effectiveness of the study drug, ACTH Gel in people diagnosed with dermatomyositis a disease that causes muscle weakness and is associated with a rash (DM) or polymyositis (PM) a disease that causes muscle weakness without a rash. The study docto...
What is the current status of trial NCT01906372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01906372?
The interventions under investigation include: Adrenocorticotropic Hormone Gel (DRUG).
Who is sponsoring clinical trial NCT01906372?
This trial is sponsored by Rohit Aggarwal, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.